Abstract Prizes 2009

[f]Abstract Prizes 2009[/f] [u][f]Clinical Research[/f][/u] J. Ardill, et al, Belfast, United Kingdom. Assessment of the sensitivity of circulating neurokinin A and chromogranin A to changing prognosis in patients with serotonin-producing endocrine tumors of the ileum and colon A. Astudillo, et al, Oviedo, Spain. Snail as epithelial-mesenchymal transition marker in neuroendocrine tumors of the lung [f]R. Bettini, et al, Verona, Italy. Non-functioning pancreatic endocrine tumors: Any correlation of tumor size with malignancy?[/f] P. Brown, et al, The Woodlands, TX, USA. LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome A. Falchetti, et al, Florence, Italy. Early identification of the MEN1-associated gastrinomas: Use of the secretin test in the experience of the Center for Hereditary Endocrine Tumors of Florence, Italy P. Ferolla, et al, Perugia, Italy. Prevalence and features of MEN1 in a large cohort of gastroenteropancreatic and thoracic NET: Data from a large multicentric Italian database L. Krolicki, et al, Warsaw, Poland. Clinical results of PRRT with 90Y-DOTA TATE and 90Y/177Lu-DOTATATE - what is better for therapy? T. Meyer, et al, London, United Kingdom. Chemotherapy with 5-Fluorouracil, cisplatin and streptozocin (FCiSt) for neuroendocrine tumors A. Rinke, et al, Marburg, Germany. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group [f]J. Strosberg, et al, Tampa, FL, USA. First line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide[/f] [u][f]Basic/Translational Research[/f][/u] A. Couvelard, et al, Clichy, France. Molecular predictors of response to chemotherapy in advanced/metastatic gastroenteropancreatic endocrine tumors [f]A. Kalhan, et al, Cardiff, United Kingdom. Adenosine A2 receptor signalling mediates chromogranin A secretion from neuroendocrine tumors[/f] [f]M. Mei, et al, Beijing, China. Dual expression of α-internexin in pancreatic endocrine tumors and its implications[/f] [center] *** [/center] [color=]Two other abstract authors, each who presented their work in poster format at the Granada conference, also received monetary awards for their work:[/color] [f]P. Szybinski, et al, Cracow, Poland[/f]: [k]Colorectal neuroendocrine tumors of the gastroenteropancreatic tract (GEP-NET) - minimal invasive surgery[/k] [k]Radio-guided surgery for the intraoperative detection of neuroendocrine tumors of the gastroenteropancreatic tract (GEP-NET)[/k] [f]V. Prasad, et al, Bad Berka, Germany[/f]: [k]Impact of Peptide Receptor Radionuclide Therapy using Y-90 DOTA-TATE/Lu-177 DOTA-TATE on renal tubular function: Long-term follow-up Management of neuroendocrine tumors of the rectum (rNET) using Ga-68 somatostatin receptor PET/CT (SR-PET/CT) and Peptide Receptor Radionuclide Therapy (PRRT) Pancreatic neuroendocrine tumor (pNET): Survival benefits and efficacy of Peptide Receptor Radionuclide Therapy (PRRT) using Y-90/Lu-177 DOTA-TATE Peptide Receptor Radionuclide Therapy (PRRT) of neuroendocrine tumor patients with carcinoid heart disease[/k]

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.


Wishing you all the best,

The entire ENETS team